Diplomat Pharmacy, Inc. (NYSE:DPLO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “

DPLO has been the subject of a number of other reports. Mizuho upped their target price on Diplomat Pharmacy from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, May 16th. BidaskClub lowered Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. Bank of America Corporation upped their target price on Diplomat Pharmacy from $17.00 to $18.50 and gave the company a “neutral” rating in a research note on Thursday, May 25th. Cowen and Company upped their target price on Diplomat Pharmacy from $12.00 to $17.00 and gave the company a “market perform” rating in a research note on Tuesday, May 9th. Finally, Barclays PLC set a $20.00 target price on Diplomat Pharmacy and gave the company a “buy” rating in a research note on Tuesday, May 9th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $21.07.

Diplomat Pharmacy (DPLO) traded up 0.92% during mid-day trading on Monday, reaching $15.30. 426,793 shares of the company’s stock traded hands. The stock has a market capitalization of $1.03 billion, a PE ratio of 60.96 and a beta of 0.64. Diplomat Pharmacy has a 12 month low of $12.25 and a 12 month high of $38.94. The firm’s 50-day moving average price is $17.70 and its 200 day moving average price is $15.30.

Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, May 8th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.04. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Diplomat Pharmacy had a return on equity of 7.91% and a net margin of 0.38%. Diplomat Pharmacy’s revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.23 earnings per share. Equities research analysts predict that Diplomat Pharmacy will post $0.65 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Diplomat Pharmacy, Inc. (DPLO) Downgraded by Zacks Investment Research to “Sell”” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/17/diplomat-pharmacy-inc-dplo-downgraded-by-zacks-investment-research-to-sell.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DPLO. State of Alaska Department of Revenue raised its position in Diplomat Pharmacy by 80.0% in the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after buying an additional 3,833 shares in the last quarter. Bank of Montreal Can raised its position in Diplomat Pharmacy by 3.0% in the second quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock valued at $172,000 after buying an additional 340 shares in the last quarter. Capstone Asset Management Co. raised its position in Diplomat Pharmacy by 0.5% in the second quarter. Capstone Asset Management Co. now owns 24,430 shares of the company’s stock valued at $362,000 after buying an additional 120 shares in the last quarter. Redmile Group LLC raised its position in Diplomat Pharmacy by 718.1% in the first quarter. Redmile Group LLC now owns 1,254,342 shares of the company’s stock valued at $20,007,000 after buying an additional 1,101,025 shares in the last quarter. Finally, Endurant Capital Management LP bought a new position in Diplomat Pharmacy during the first quarter valued at about $1,356,000. Hedge funds and other institutional investors own 72.55% of the company’s stock.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.